Last reviewed 2026-05-13 · How we verify

Single Ascending Doses of EB8018

Enterome · Phase 1 active Small molecule

Single Ascending Doses of EB8018 is a Small molecule drug developed by Enterome. It is currently in Phase 1 development.

At a glance

Generic name	Single Ascending Doses of EB8018
Sponsor	Enterome
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-in-Human Single and Multiple Dose of EB8018 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Single Ascending Doses of EB8018 CI brief — competitive landscape report
Single Ascending Doses of EB8018 updates RSS · CI watch RSS
Enterome portfolio CI

Frequently asked questions about Single Ascending Doses of EB8018

What is Single Ascending Doses of EB8018?

Single Ascending Doses of EB8018 is a Small molecule drug developed by Enterome.

Who makes Single Ascending Doses of EB8018?

Single Ascending Doses of EB8018 is developed by Enterome (see full Enterome pipeline at /company/enterome).

What development phase is Single Ascending Doses of EB8018 in?

Single Ascending Doses of EB8018 is in Phase 1.

Manufacturer: Enterome — full pipeline
Compare: Single Ascending Doses of EB8018 vs similar drugs
Pricing: Single Ascending Doses of EB8018 cost, discount & access